PT-141 — 10mg | Cyclic Melanocortin Agonist (MC4R)

PT-141 (also known as Bremelanotide or PT 141) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from α-MSH (alpha-melanocyte-stimulating hormone). The peptide was originally developed by Palatin Technologies as a research compound for melanocortin receptor pharmacology and was subsequently FDA-approved as Vyleesi® in 2019 for hypoactive sexual desire disorder in premenopausal women. Structurally, PT-141 features an N-acetylated norleucine substitution at position 1 and a stabilizing lactam bridge between Asp² and Lys⁷, creating a constrained cyclic structure that enhances receptor binding stability and metabolic resistance. PT-141 functions as a non-selective melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R, with primary research interest focused on MC4R agonism in the central nervous system. The compound has been investigated extensively in preclinical research for melanocortin receptor pharmacology, MC4R signaling, hypothalamic neuroendocrine research, and structure-activity relationship (SAR) studies of cyclic melanocortin analogs.

Benefits (Research Focus)

• Melanocortin receptor agonism — studied as a non-selective MC1R/MC3R/MC4R/MC5R agonist for receptor pharmacology research

• MC4R signaling research — investigated for central nervous system MC4R pathway pharmacology

• Cyclic peptide stability — explored for the role of the Asp²-Lys⁷ lactam bridge in metabolic stability and receptor binding

• Hypothalamic neuroendocrinology — examined for melanocortin signaling in hypothalamic neuron populations

• SAR comparator — researched as a reference compound versus other melanocortin analogs (e.g., melanotan II, MT-II, SHU 9119)

What Researchers Look At

• MC1R, MC3R, MC4R, and MC5R receptor binding affinity and selectivity profiles

• cAMP signaling and downstream MC4R pathway activation in receptor expression systems

• Hypothalamic c-Fos expression and neuronal activation patterns following melanocortin agonism

• Plasma pharmacokinetic profiles and central versus peripheral distribution

• Comparative pharmacology versus α-MSH, melanotan II, and other linear and cyclic melanocortin analogs

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 10 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: PT-141 (Bremelanotide)

• Synonyms: Bremelanotide; PT 141; PT141; Vyleesi (FDA-approved brand name)

• Class: Cyclic heptapeptide; non-selective melanocortin receptor agonist (MC1R/MC3R/MC4R/MC5R); α-MSH analog

• Sequence: Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH

• Structural features: N-acetylated norleucine at position 1; lactam bridge between Asp² and Lys⁷; 7 amino acids in cyclic backbone

• Formula / M.W.: C₅₀H₆₈N₁₄O₁₀, ~1025.18 g/mol

• CAS: 189691-06-3

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• PT-141 Batch COA — October 8, 2025

• PT-141 VPeptide Canada — March 27, 2026

• PT-141 VPeptide Canada — August 27, 2026